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ABSTRACT 
Objective: The aim of this study is to develop and in vitro evaluation of prepared fluconazole nanogel for seborrheic dermatitis  
Methods: Fluconazole nanogel was formulated to act against seborrheic dermatitis. The fluconazole nanoparticles were prepared by a simplified 
evaporation method and evaluated for particle size, entrapment efficiency, and percent in vitro drug release. The nanogel was also characterized 
based on parameters like particle size, percent entrapment efficiency, shape surface morphology, rheological properties, in vitro release R² = 0.9046, 
and release kinetics.  
Results: The nanoparticle with a combination of Eudragit RS and Tween 80 showed the best result with particle size in the range of 119.0 nm to 
149.5 nm, with a cumulative percent drug release of 95 % up to 18 h. The formulated nanogel with optimum concentration of HPMC authenticate 
with particle size 149.50±0.5 with maximum drug release (92.13±0.32) %. 
Conclusion: Different percentages of polymers (ethyl-cellulose, eudragit, and tween 80) are used as variable components in the formulation of 
nanogel. The optimized batch showed good physical properties (flow index, spreadability, and viscosity) along with rapid drug release. Therefore, it 
can be concluded that nanogel containing fluconazole has potential application in topical delivery. 
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INTRODUCTION  
Seborrheic dermatitis is a topical skin inflammatory disorder, 
mainly characterized by yellow-grey scales and poorly defined 
erythematous patches. It affects the sebum-rich areas such as skin, 
scalp, nasolabial folds, ears, eyebrows, and chest [1]. The frequency 
is more common in men than in women. The occurrence of the 
lesion also depends on the weather conditions [2, 3]. However, 
sunlight has some evidence to develop seborrheic dermatitis 
following psoralen+UVA therapy, also known as PUVA. Treatment of 
seborrheic dermatitis aims at reducing inflammatory processes and 
decreasing sebum production [4]. 
Besides, recent studies have revealed that tea tree oil (Melaleuca 
oil), honey, and cinnamic acid have antifungal activity against 
Malassezia species, which may be of benefit in the treatment of 
seborrheic dermatitis [5]. With the wide availability of preparations, 
including creams, shampoos, and oral formulations, antifungal 
agents are safe and effective in the treatment of seborrheic 
dermatitis [6]. This may, in part, be due to an abnormal or 
inflammatory immune response to these yeasts.  
A variety of treatment modalities are available, including the 
eradication of the fungus, reducing, or treating the inflammatory 
process, and decreasing sebum production. These included some 
antifungal agents, corticosteroids, immunomodulators, and 
keratolytic. The characterization of these classes of drugs such as the 
anti-inflammatory properties inherent in many of the antifungal 
agents as well as the keratolytic properties of selenium, zinc, and tar 
preparations. The azoles including bifonazole, itraconazole, 
fluconazole, and ketoconazole represent the largest class of 
antifungals used in the treatment of fungal infection [7]. 
Antifungal agents are the mainstay of anti-seborrheic therapy, 
mostly in the azole form. These agents work by inhibiting ergosterol, 
an important component of the fungal cell wall, via interference with 
the fungal cytochrome P-450 (CYP 450) system. This causes an 
increase in the production of sterol precursors, a fungistatic process 
that does not allow the fungus to grow or reproduce. Fluconazole-
first generation triazole is selected for the treatment of seborrheic 
dermatitis as it has fewer side effects but the weakest binding to 
human CYP 450 [4]. The nanogel of the drug Fluconazole shows 
better results as it has advantages over the simple topical products 
available in the market [5]. 
The present investigation aimed at formulating fluconazole nanogel, 
effective against seborrheic dermatitis. The research was mainly 
composed of two steps viz. loading of fluconazole to nanoparticle 
and second to incorporate these nanoparticles to a gel base forming 
nanogel. Nanogels are three-dimensional hydrogel materials 
crosslinked with swell polymers, increasing their efficiency to hold 
water. These are highly hydrophilic, increasing their 
biocompatibility to load drug molecules.  
MATERIALS AND METHODS 
Materials  
Fluconazole was received as a gift sample from Unichem Laboratory, 
Ghaziabad. Eudragit RS was purchased from Sigma-Aldrich Pvt Ltd. 
Ethyl-cellulose and tween 80 were purchased from CDH Pvt. Ltd., 
New Delhi. All the solvents used were of analytical grade. 
Methods 
Preparation of fluconazole nanoparticle 
Fluconazole nanoparticles were prepared by using simplified 
evaporation methods [8]. On the variable of different concentrations 
of polymers, six formulations were formulated (table 1). The 
polymers were mixed with a solvent (ethanol), forming an organic 
phase following the addition of fluconazole. The aqueous phase was 
prepared separately by dissolving tween 80 with water. Both phases 
were mixed by adding organic phase dropwise with continuous 
stirring [9]. The organic phase was later allowed to evaporate 
overnight. The mixture is then centrifuged to separate the 
nanoparticles [10]. 
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Table 1: Formulation table for preparing fluconazole nanoparticles 
S. No. Formulation code Ethylcellulose (mg) Eudragit RS 100 (mg) Tween 80 (%) 
1 A1 450 - 0.5 
2 A2 450 - 1.0 
3 A3 450 - 1.5 
4 A4 - 450 0.5 
5 A5 - 450 1.0 
6 A6 - 450 1.5 
 
Characterization parameters for fluconazole nanoparticles  
Particle size and polydispersity index (PDI) 
The undiluted sample of nanoparticles were transferred in cuvette and 
particle size was measured by using dynamic light scattering (DLS) 
apparatus. The results were analyzed and performed in triplicate [11]. 
Percentage drug entrapment efficiency (%) 
1 ml of nanoparticle sample is taken for centrifugation at 7168 RCF 
(relative centrifugal force) for 50 min. The supernatant was 
collected, washed, and filtered through membrane (0.45 micron) 
filter paper. The absorbance of the sample was noted, and the actual 
entrapped drug was calculated using the below-mentioned formula: 
The readings were taken in triplicate [12].  




In vitro drug release study 
100 
Keshary-Chien cell (K-C) was used for performing in vitro release study. 
These are thermo-regulated by using a water jacket at 37±0.5 °C. 
Phosphate buffer (pH 6.5) was used as a receptor medium. 
Nanoparticles (equivalent to 1 mg of fluconazole) were placed in the 
donor compartment. Dialysis membrane 70 (Hi-Media, Mumbai, India) 
having a pore size of 2.4 nm and a molecular weight cut-off between 
12,000-14,000 Da was used as a donor compartment. At predetermined 
time intervals, 5 ml of the samples were withdrawn from the receiver 
compartment and replaced by the same volume of freshly prepared PBS 
(pH 6.5). The samples were analyzed at the wavelength of 254 nm using 
a UV spectrophotometer. The readings were taken in triplicate [13]. 
Preparation of fluconazole nanogel  
The prepared and optimized nanoparticles were loaded to a 
hydrogel base to form a fluconazole nanogel. The hydrogel was 
formulated using ingredients and quantities as mentioned in table 2. 
Three polymers were used to optimize the hydrogel formulation, the 
three polymers used are carbopol 940, HPMC, and methylcellulose. 
Different concentrations of polymer aqueous solution (antisolvent) 
were prepared by dispersing the calculated amount of polymer in 
warm water with constant stirring. Then add the previous mixture 
containing the drug using a syringe to a polymer mixture followed 
by constant stirring at 7168 RCF by a homogenizer. Methyl and 
propylparaben as preservatives were added slowly with continuous 
stirring until gel formation [14]. 
 
Table 2: Formulation table for preparing fluconazole nanogel 
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
1 Fluconazole (mg) 1 1 1 1 1 1 1 1 
2. Carbopol 940 0.5 1 - - - - - - 
3. Methyl cellulose - - 2 4 - - - - 
4. HPMC - - - - 1.5 2 - - 
5. Pectin - - - - - - 3 4 
6. Glycerine 10 10 10 10 10 10 10 10 
7. Propylene glycol 20 20 20 20 20 20 20 20 
8. Methylparaben 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
9. Propylparaben 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
10. Purified water to 100 100 100 100 100 100 100 100 
 
Characterization of fluconazole nanogel 
Rheological parameters 
Viscosity 
Brookfield viscometer was used to analyze the viscosity of the 
formulated nanogel. The formulated nanogel was taken in beakers 
and analyzed by setting spindle number and rpm. The readings were 
taken in triplicate.  
Spreadability 
The gel was evaluated by using a glass slide method. The formulated 
gel was kept between the two sides within a pre-marked circle (1 
cm). The pre-weighted plate was kept above the gel for 5 min [12]. 
The increase in the diameter due to gel spreading was noted and 
calculated using the formula mentioned below:  
Spreadability =mass× length/time 
pH determination 
pH of the nanogel formulation was measured using a pH meter. For 
this determination, 1 g of nanogel was weighed and dispersed in 10 
ml of distilled water. This was kept for 4–5 min for taking the actual 
pH value. The reading was taken in triplicate.  
Drug content 
Nanogel was dissolved in 10 ml of ethanol and thereby drug content 
was measured. The mixture was centrifuged at 448 RCF for 1 h. The 
supernatant liquid was withdrawn, and samples were analyzed 
using a UV spectrophotometer at 260 nm.  
Particle shape and surface morphology 
The particle shape and surface morphology of prepared nanogel was 
visualized by scanning electron microscopes (Cart Zeiss EV018). One 
drop of the sample was placed on a slide, and excess water was left 
to dry at room temperature. The testing slides of samples were 
prepared by lightly sprinkling samples on double-sided adhesive 
tape on an aluminum stub. The samples were coated with gold to a 
thickness of 200 to 500 °A under an argon atmosphere using a gold 
sputter module in a high vacuum evaporator. The samples were then 
randomly scanned, and photomicrographs were taken at different 
magnifications with SEM [15].  
Transmission electron microscopy (TEM) 
TEM was used to visualize (morphology and structure) of nanogel. 
The samples were dried on a copper grid and adsorbed with filter 
paper. After drying, the sample was viewed under the microscope at 
different magnifications at an accelerating voltage of 100 kV. 
Drug release kinetics studies 
From the characterization parameters one optimized formulation 
was selected and evaluated for release kinetics to understand the 
release mechanism of the formulated nanogel. For this, data 
obtained from in vitro drug release was plotted for zero-order 
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equation, first-order equation, Korsmeyer’s Peppas equation, and 
Higuchi’s equation.  
Drug-excipients compatibility studies 
While formulating fluconazole nanogel, interaction studies were 
performed. No interaction was found while performing interaction 
studies using Fourier transform Infrared Spectroscopy technique. 
The results have been illustrated in fig. 1.  
In vitro drug release studies 
The various nanogel batches were evaluated using the Keshary-
Chien cell (K-C) cell. The procedure used for in vitro release study 
was the same as employed for fluconazole nanoparticles.  
RESULTS AND DISCUSSION 
Preparation of fluconazole nanoparticle 
Fluconazole nanoparticles were prepared by the solvent 
evaporation method in six different batches.  
Characterization for fluconazole nanoparticles 
Nanoparticles of fluconazole were successfully prepared and 
optimized to find out the best formulation which is to be loaded to a 
hydrogel base. The optimization was based on particle size, percent 
entrapment efficiency, and in vitro drug release. 
Drug-excipients compatibility studies 
Particle size and polydispersity index and percentage drug 
entrapment efficiency (%) 
The result obtained from particle size analysis and %EE have 
been mentioned in table 3. From the results obtained it can be 
concluded that Formulation A6 (particle size of 149.50±0.5 nm) 
shows better % EE and has optimum percent drug release. The 
smaller size of nanoparticles will help to increase the 
permeation of the drug through the biological membrane at the 
target site indicating its efficiency to deliver the drug through a 
topical route [16]. 
 
 
Fig. 1: Fourier transformation infra-red radiation (FTIR) images showing drug-excipient interaction of sample: (a) Drug and excipients, 
(b) drug (fluconazole), and (c) excipients. No new peak in the sample indicates drug excipient compatibility 
 
Table 3: Particle size and percent entrapment efficiency 
Formulation code Particle size (nm) EE% 
A1 119.46±0.5 83.66±0.58 
A2 110.83±0.76 91.36±1.1 
A3 140.83±1.04 79.50±0.88 
A4 150.36±0.47 94.20±0.88 
A5 135.93±0.95 95.80±0.55 
A6 149.50±0.5 96.03±0.96 
 
In vitro drug release of fluconazole nanoparticles 
The in vitro drug release obtained from fluconazole nanoparticles 
has been depicted in fig. 2. The optimized formulation (A6) was 
selected and further loaded to a nanogel base. 
Characterization of fluconazole nanogel 
An optimized formulation of fluconazole nanoparticles was 
successfully loaded to form nanogel.  
Results obtained from physical and rheological parameters have 
been depicted in table 4, which concluded that the formulation 
exhibited good viscosity, spreadability, and an optimum pH. The 
formulation was having a good viscosity, spreadability, 
homogeneity, pH, and visual inspection. The result obtained showed 
that the formulation is having an optimum viscosity and 
spreadability. Rheological properties such as flow index, flow 
behavior, and Coefficient of determination have been illustrated in 
table 4. 
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Fig. 2: Cumulative percent in vitro drug release of fluconazole nanoparticles showing that half of the nanoparticles are released in the first 
2 hr and 90% release occurs in 8 hr. Among all batches, the A6 batch showed maximum cumulative release with 149.50±0.5 particle size 
and 96.03±0.96 entrapment efficiency and n=3, mean±SD 
 
Table 4: Evaluation of physical and rheological properties of fluconazole nanogel batches 













F1 Shiny transparent 4.5±0.21 6.1±0.2 0.916±0.04 0.238±0.00 1709±92.1 Shear-thinning 
F2 Shiny transparent 4±0.95 5.99±0.29 0.9291±0.04 0.235±0.01 1918±47.9 Shear-thinning 
F3 Transparent  4.5±0.2 6.1±0.12 0.9976±0.04 0.225±0.01 1449±71.8 Shear-thinning 
F4 Transparent  3.6±0.15 6.13±0.8 0.9823±0.04 0.210±0.01 2083±98.1 Shear-thinning 
F5 Pale, translucent 5±0.23 5.60±0.15 0.908±0.04 0.230±0.00 1012±48.2 Shear-thinning 
F6 Pale, translucent 5±0.2 5.67±0.14 0.908±0.04 0.230±0.01 1036±50.6 Shear-thinning 
F7 Opaque, buff 5±0.22 3.6±0.9 0.9304±0.04 0.121±0.00 1247±61.4 Shear-thinning 
F8 Opaque, buff 3.5±0.12 3.7±1.2 0.9819±0.04 0.143±0.00 2289±110.3 Shear-thinning 
 
Drug content  
The formulated fluconazole nanogel was evaluated for drug content 
parameters. The drug content was found to be in the range of 
75.30±0.43 % to 95.33±0.49%. The results have been shown in table 5.  
 
Table 5: Drug content of fluconazole nanogel batches 











The nanogel was visualized by scanning electron microscopy (SEM). 
They were found to be spherical, having a smooth surface (fig. 3). 
The average range of particle size was found to be 101.9 nm to 127.5 
nm, having the particle size in the optimal range, which is having 
excellent morphological properties with minimum toxicity [17].  
TEM 
The sample was viewed under the microscope at different 
magnifications at an accelerating voltage of 100 kV. The prepared 
nanoparticles, showing the spherical shape and particle size of 100-
130 nm. 
 
Fig. 3: SEM (scanning electron microscopy) of optimized 




Fig. 4: TEM (transition electron microscopy) of fluconazole 
optimized nanogel formulation showing the spherical shape 
and size of average±112 nm, n=3, mean±TEM 
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In vitro drug release 
The in vitro release study showed the release of above 90 % up to 18 
h. (fig. 5). The model or equation that best fits the release data was 
evaluated by correlation coefficient (r) and the value of n, 
particularly for Korsmeyer Peppas’s Equation. The release study 
was best explained by Higuchi’s equation, shown in fig. 6. From the 
above, it is indicated that the drug release will be diffusion 
controlled, depending on the swelling criteria of cross-linked 
polymers present in the hydrogel 
  
 
Fig. 5: Cumulative percent in vitro drug release of F1-F8 batches of fluconazole nanogel shows around 50% of drugs were released in the 
starting first 10 h of total release and 90% drug releases in 18 h, with maximum release of F5, n=3, mean±SD 
 
 
Fig. 6: Drug release kinetics of optimized fluconazole nanogel showed the highest linearity was R2 = 0.971, followed by zero-order (R2= 
0.853), Korsmeyer-Peppas model (R2= 0.559), and first-order equation (R2
 
 = 0.412). All values are expressed as, n = 6, mean±SD 
CONCLUSION 
Fluconazole was successfully incorporated into a gel base. The 
nanogel shows a good flow index, spreadability, and viscosity. The 
release profile shows drug release for a prolonged period. The 
nanogel attains a good percentage of drug content in the 
formulation. Therefore, it can be concluded that nanogel containing 
fluconazole has potential application in topical delivery. 
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